Scarica l'app Stockscreener
108.74
1.08%
-1.19
Dopo l'orario di chiusura:
108.94
0.20
+0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$109.93
Aprire:
$109.01
Volume 24 ore:
1.80M
Relative Volume:
0.73
Capitalizzazione di mercato:
$14.12B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-25.65
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
+6.46%
1M Prestazione:
+4.39%
6M Prestazione:
+113.97%
1 anno Prestazione:
+197.19%
Intervallo 1D:
$106.42
$111.50
Intervallo di 1 settimana:
$97.31
$113.91
Portata 52W:
$34.80
$113.91
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
108.74 | 14.28B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
606.50 | 231.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.00 | 166.39B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
712.39 | 57.06B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
243.19 | 41.60B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
145.76 | 41.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Aug Swings: How strong is Guardant Health Inc. stock balance sheetJuly 2025 Market Mood & Technical Buy Zone Confirmation - ulpravda.ru
How Guardant Health Inc. stock compares to industry benchmarks2025 EndofYear Setup & Expert Curated Trade Setups - ulpravda.ru
Can Guardant Health Inc. stock continue upward trendWeekly Investment Summary & Reliable Breakout Forecasts - ulpravda.ru
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families - The Joplin Globe
Will Guardant Health Inc. stock deliver better than expected guidanceTrendline Breakouts & Rapid Wealth Accumulation - ulpravda.ru
Assessing Guardant Health (GH) Valuation After Analyst Upgrades And New Cancer Test Partnerships - Yahoo Finance
Guardant Health stock hits 52-week high at 112.43 USD By Investing.com - Investing.com Nigeria
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next - TechStock²
GH Virtual Meeting Scheduled by BTIG for January 12 - GuruFocus
Guardant Health (NASDAQ:GH) Stock Rating Lowered by Evercore ISI - MarketBeat
GH: Evercore ISI Group Downgrades Guardant Health While Raising Price Target | GH Stock News - GuruFocus
GH: Guggenheim Raises Price Target for Guardant Health to $115 | - GuruFocus
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Guardant Health, Inc. $GH - MarketBeat
Allspring Global Investments Holdings LLC Makes New $39.52 Million Investment in Guardant Health, Inc. $GH - MarketBeat
What analysts say about Guardant Health Inc stockBear Market Strategies & Explosive Growth Opportunities - earlytimes.in
Calamos Advisors LLC Takes $2.78 Million Position in Guardant Health, Inc. $GH - MarketBeat
Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside - Finviz
Behavioral Patterns of GH and Institutional Flows - Stock Traders Daily
Osaic Holdings Inc. Grows Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook - MSN
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Joplin Globe
Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening - The Joplin Globe
Guardant Health, Inc. (GH) Stock Analysis: A Precision Oncology Leader with Robust Growth Potential - DirectorsTalk Interviews
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - The Motley Fool
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth - MSN
Capricorn Fund Managers Ltd Takes $2.26 Million Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genomics in Cancer Care Market to Reach USD 72.87 Billion by 2033 | - openPR.com
Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth - Yahoo Finance
Guardant Health (GH) Leads Healthcare Stocks with 226.48% YTD Ga - GuruFocus
Guardant Health is the top performing healthcare services stock YTD (GH:NASDAQ) - Seeking Alpha
7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey
Guardant Health (GH) Receives Buy Rating and $125 Price Target f - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Guardant Health (NASDAQ:GH) Stock Price - MarketBeat
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy - Yahoo Finance
(GH) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Why Guardant Health Inc. (5GH) stock could be top winnerWeekly Investment Recap & Weekly Momentum Picks - ulpravda.ru
How Guardant Health Inc. (5GH) stock reacts to stronger dollarGap Up & Weekly Sector Rotation Insights - DonanımHaber
First Week of February 2026 Options Trading For Guardant Health (GH) - Nasdaq
How strong is Guardant Health Inc. stock balance sheetJuly 2025 Highlights & Weekly Breakout Stock Alerts - DonanımHaber
Can Guardant Health Inc. (5GH) stock hold up in economic slowdown2025 Big Picture & Low Drawdown Trading Techniques - DonanımHaber
Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) CIO reports RSU vesting and tax-share withholding - Stock Titan
Guardant Health Insider Move Sparks Fresh Buzz on Wall Street - TipRanks
[Form 4] Guardant Health, Inc. Insider Trading Activity - Stock Titan
Guardant Health (GH) CMO Craig Eagle reports RSU vesting and tax share sale - Stock Titan
Guardant Health (NASDAQ:GH) Director Sells $11,769.36 in Stock - MarketBeat
Dir Tariq Sells 116 ($11.8K) Of Guardant Health Inc [GH] - TradingView — Track All Markets
Guardant Health (GH) director exercises RSUs into 232 common shares - Stock Titan
Guardant Health (GH) director reports 116-share stock sale and holdings - Stock Titan
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
2.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):